Global Inflammatory Bowel Disease (Crohn's Disease, Ulcerative Colitis) Market Analysis, 2016-2020 & 2021-2026 by Disease Indication, Drug Class, Distribution Channel - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Inflammatory Bowel Disease (IBD) Market - Analysis By Disease Indication (Crohn's Disease, Ulcerative Colitis), Drug Class, Distribution Channel, By Region, By Country (2021 Edition): Market Insights, Covid-19 Pandemic, Competition and Forecast (2021-2026)" report has been added to ResearchAndMarkets.com's offering.

The Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020, has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn's Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression.

Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol consumption and cigarette smoking are likely to contribute towards the growth of the IBD market.

Additionally, rise in investments in building a robust pipeline for IBD, increase in lifestyle-related risk factors and growing popularity of prebiotic and probiotic foods are likely to boost the growth of the global market during the forecast period.

The North America region dominates the market. In North America, rising prevalence and incidence of IBD across the region is the major driving factor for the market. Moreover, an increasing number of cigarette-smokers in United States and significant funding in the IBD field in Canada is further estimated to boost the growth of the IBD market in the region.

The IBD market in North America has remained at the forefront in terms of growth opportunities as well as developments in the field of Crohn's Disease over the years. The region is likely to continue to account for a significant piece of the revenue pie over the next few years as well, thanks to the presence of several pharmaceutical and biosciences companies and the presence of numerous leading players in the field of Crohn's Disease.

Additionally, increasing geriatric population base and prevalence of Ulcerative Colitis and Crohn's disease and also well-developed healthcare expenditure coupled with increased per capita healthcare expenditure across regions would enhance the growth of the market during the forecast period.

Key Topics Covered:

1. Report Scope and Methodology

1.1 Scope of the Report

1.2 Research Methodology

1.3 Executive Summary

2. Strategic Recommendations

3. Global Inflammatory Bowel Disease Market: Product Outlook

4. Global Inflammatory Bowel Disease Market: An Analysis

4.1 Market Size, By Value, Year 2016-2026

4.2 COVID-19 Impact on Inflammatory Bowel Disease Market

5. Global Inflammatory Bowel Disease Market Segmentation By Disease Indication (By Value)

5.1 Competitive Scenario of Global Inflammatory Bowel Disease Market: By Disease Indication

5.2 Crohn's Disease - Market Size and Forecast (2016-2026)

5.3 Ulcerative Colitis - Market Size and Forecast (2016-2026)

6. Global Inflammatory Bowel Disease Market Segmentation By Drug Class (By Value)

6.1 Competitive Scenario of Global Inflammatory Bowel Disease Market: By Drug Class

6.2 TNF Inhibitors - Market Size and Forecast (2016-2026)

6.3 Aminosalicylates - Market Size and Forecast (2016-2026)

6.4 Integrin Antagonists - Market Size and Forecast (2016-2026)

6.5 Others - Market Size and Forecast (2016-2026)

7. Global Inflammatory Bowel Disease Market Segmentation By Distribution Channel (By Value)

7.1 Competitive Scenario of Global Inflammatory Bowel Disease Market: By Distribution Channel

7.2 Hospital Pharmacies - Market Size and Forecast (2016-2026)

7.3 Retail Pharmacies - Market Size and Forecast (2016-2026)

7.4 Online Pharmacies - Market Size and Forecast (2016-2026)

8. Global Inflammatory Bowel Disease Market: Regional Analysis

8.1 Competitive Scenario of Global Inflammatory Bowel Disease Market: By Region

9. North America Inflammatory Bowel Disease Market: An Analysis (2016-2026)

9.1 North America Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value

9.2 North America Inflammatory Bowel Disease Market - Prominent Companies

9.3 Market Segmentation By Disease Indication (Crohn's Disease and Ulcerative Colitis.)

9.4 Market Segmentation By Drug Class (TNF Inhibitors, Aminosalicylates, Integrin Antagonists and Others.)

9.5 Market Segmentation By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies.)

9.6 North America Inflammatory Bowel Disease Market: Country Analysis

9.7 Market Opportunity Chart of North America Inflammatory Bowel Disease Market - By Country, By Value (Year-2026)

9.8 Competitive Scenario of North America - By Country

9.9 United States Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value

9.10 United States Inflammatory Bowel Disease Market Leading Companies

9.11 United States Inflammatory Bowel Disease Market - Segmentation By Disease Indication, Drug Class, Distribution Channel.

9.12 Canada Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value

9.13 Canada Inflammatory Bowel Disease Market - Segmentation By Disease Indication, Drug Class and Distribution Channel.

10. Europe Inflammatory Bowel Disease Market: An Analysis (2016-2026)

11. Asia Pacific Inflammatory Bowel Disease Market: An Analysis (2016-2026)

12. Global Inflammatory Bowel Disease Market Dynamics

12.1 Global Inflammatory Bowel Disease Market Drivers

12.2 Global Inflammatory Bowel Disease Market Restraints

12.3 Global Inflammatory Bowel Disease Market Trends

13. Market Attractiveness and Strategic Analysis

13.1 Market Attractiveness

13.2 Strategic Analysis

13.2.1 Mergers and Acquisitions

13.2.2 Recent Industry Developments

14. Competitive Landscape

14.1 Market Share Analysis

15. Inflammatory Bowel Disease Pipeline Development

15.1 Emerging Therapies in Inflammatory Bowel Disease

16. Company Profiles (Business Description, Financial Analysis, Business Strategy)

16.1 Johnson & Johnson

16.2 AbbVie Inc.

16.3 Takeda

16.4 Pfizer

16.5 Roche

16.6 Celgene

16.7 GlaxoSmithKline

16.8 Novartis

16.9 UCB

16.10 Eli Lilly & Company

For more information about this report visit https://www.researchandmarkets.com/r/gbvx9b

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900